PMID- 36342562
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 38
IP  - 2
DP  - 2024 Apr
TI  - Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular 
      Repolarization Markers in Heart Failure with Reduced Ejection Fraction.
PG  - 327-333
LID - 10.1007/s10557-022-07396-y [doi]
AB  - BACKGROUND AND AIM: Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to 
      optimal medical therapy have been shown to reduce the risk of cardiovascular 
      death and recurrent heart failure (HF) hospitalization in HF patients. We aimed 
      to evaluate the effect of SGLT2 inhibitors on the ventricular repolarization 
      markers (VRM) in patients with HF with reduced ejection fraction (HFrEF). 
      METHODS: 51 patients with HFrEF who had symptoms New York Heart Association 
      (NYHA) class II-IV despite optimal medical treatment and were added SGLT2 
      inhibitors to their treatment were included in the study. Electrocardiography 
      (ECG) and laboratory results obtained before the treatment and at the first-month 
      follow-up visit were compared. QT, QTc (corrected by Bazett formula), QT 
      dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, 
      and Tp-e/QTc ratios were measured and defined as VRM. RESULTS: A significant 
      decrease was observed in HR, QT, QTc intervals, and QTd compared to 
      pre-treatment. While the mean Tp-e interval was 101.5 +/- 11.7 ms before treatment, 
      it decreased to 93.1 +/- 12.7 ms after treatment (p < 0.001). There was a 
      significant decrease in N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
      levels after treatment [2859 +/- 681vs.1266 +/- 763, respectively (p < 0.001)] and 
      QTd, Tp-e interval, and Tp-e/QTc ratio was positively correlated with the change 
      in NT-proBNP level. CONCLUSIONS: The addition of SGLT2 inhibitors to optimal 
      medical therapy in HFrEF patients positively changes VRM (QT, QTc, QTd, Tp-e, and 
      Tp-e/QTc).
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Yilmaz, Emre
AU  - Yilmaz E
AUID- ORCID: 0000-0002-1656-3778
AD  - Department of Cardiology, Giresun University Medical Faculty, Giresun, Turkey.
FAU - Aydin, Ertan
AU  - Aydin E
AUID- ORCID: 0000-0002-7280-5137
AD  - Department of Cardiology, Giresun University Medical Faculty, Giresun, Turkey.
FAU - Camci, Sencer
AU  - Camci S
AUID- ORCID: 0000-0003-2152-0470
AD  - Department of Cardiology, Giresun University Medical Faculty, Giresun, Turkey.
FAU - Kurt, Devrim
AU  - Kurt D
AUID- ORCID: 0000-0003-4230-3248
AD  - Department of Cardiology, Giresun University Medical Faculty, Giresun, Turkey.
FAU - Aydin, Ercan
AU  - Aydin E
AUID- ORCID: 0000-0001-8743-3762
AD  - Department of Cardiology, Kanuni Training and Research Hospital, Trabzon, Turkey. 
      ercanaydin112@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20221107
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Symporters)
SB  - IM
MH  - Humans
MH  - Electrocardiography
MH  - Glucose
MH  - *Heart Failure/diagnosis/drug therapy
MH  - Sodium
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology
MH  - Stroke Volume
MH  - *Symporters
OTO - NOTNLM
OT  - Heart failure with reduced ejection fraction
OT  - QT dispersion
OT  - SGLT-2 inhibitors
OT  - Tp-e
OT  - Tp-e/QTc
OT  - Ventricular repolarization markers
EDAT- 2022/11/08 06:00
MHDA- 2024/03/25 06:43
CRDT- 2022/11/07 11:15
PHST- 2022/10/19 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/07 11:15 [entrez]
AID - 10.1007/s10557-022-07396-y [pii]
AID - 10.1007/s10557-022-07396-y [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2024 Apr;38(2):327-333. doi: 10.1007/s10557-022-07396-y. 
      Epub 2022 Nov 7.